Imidazole-based ligands of the Src SH2 protein.

Bioorg Med Chem Lett

Aventis Pharma, Paris Research Center, Medicinal Chemistry, 102 route de Noisy, 93235 Cedex, Romainville, France.

Published: May 2002

Starting from known Src SH2 inhibitors incorporating five-membered heterocycles or benzamide scaffolds, we prepared tetrasubstituted imidazole compounds able to interact with the pY, pY+1 and pY+3 binding sites of the Src SH2 protein. The synthesis and biological data are presented.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0960-894x(02)00138-5DOI Listing

Publication Analysis

Top Keywords

src sh2
12
sh2 protein
8
imidazole-based ligands
4
ligands src
4
protein starting
4
starting src
4
sh2 inhibitors
4
inhibitors incorporating
4
incorporating five-membered
4
five-membered heterocycles
4

Similar Publications

Purpose: Mitochondrial dysfunction mediated by c-Jun N-terminal kinase (JNK) plays an important role in lipotoxic liver injury in nonalcoholic steatohepatitis (NASH). This study aims to investigate the pharmacological mechanism of Jiangzhi Granule (JZG), a Chinese herbal formula against NASH, with a focus on its regulation of JNK signaling-mediated mitochondrial function.

Methods: Hepatocytes were induced by palmitic acid (PA) for 24 h to establish an in vitro lipotoxic model, which was simultaneously treated with either JZG or vehicle control.

View Article and Find Full Text PDF

SH2 (Src Homology 2) domains play a crucial role in phosphotyrosine-mediated signaling and have emerged as promising drug targets, particularly in cancer therapy. STAT3 (Signal Transducer and Activator of Transcription 3), which contains an SH2 domain, plays a pivotal role in cancer progression and immune evasion because it facilitates the dimerization of STAT3, which is essential for their activation and subsequent nuclear translocation. SH2 domain-mediated STAT3 inhibition disrupts this binding, reduces phosphorylation of STAT3, and impairs dimerization.

View Article and Find Full Text PDF

The point mutation N642H of the signal transducer and activator of transcription 5B (STAT5B) protein is associated with aggressive and drug-resistant forms of leukemia. This mutation is thought to promote cancer due to hyperactivation of STAT5B caused by increased stability of the active, parallel dimer state. However, the molecular mechanism leading to this stabilization is not well understood as there is currently no structure of the parallel dimer.

View Article and Find Full Text PDF
Article Synopsis
  • Mirror-image proteins made from D-amino acids are promising for therapy due to their stability and minimal immune reactions.
  • Development involves creating D-target proteins, selecting L-binders via phage display, and synthesizing D-binders that interact with the natural L-targets.
  • The study focuses on D-monobodies with strong binding to the D-SH2 domain of the BCR::ABL1 kinase, showing potential for therapeutic applications by inhibiting its activity and functioning well in biological settings.
View Article and Find Full Text PDF

While ATP-site inhibitors for protein-tyrosine kinases are often effective drugs, their clinical utility can be limited by off-target activity and acquired resistance mutations due to the conserved nature of the ATP-binding site. However, combining ATP-site and allosteric kinase inhibitors can overcome these shortcomings in a double-drugging framework. Here we explored the allosteric effects of two pyrimidine diamines, PDA1 and PDA2, on the conformational dynamics and activity of the Src-family tyrosine kinase Hck, a promising drug target for acute myeloid leukemia.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!